Aim Immunotech Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Aim Immunotech has an operating margin of -11630.6%, meaning the company retains $-11631 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -15800.0% the prior year.
Aim Immunotech's revenue declined 15.8% year-over-year, from $202K to $170K. This contraction results in a growth score of 0/100.
Aim Immunotech's current ratio of 0.44 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While Aim Immunotech generated -$14.9M in operating cash flow, capex of $18K consumed most of it, leaving -$14.9M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Aim Immunotech passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Aim Immunotech generates $0.86 in operating cash flow (-$14.9M OCF vs -$17.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Aim Immunotech earns $-33.8 in operating income for every $1 of interest expense (-$19.8M vs $585K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Aim Immunotech (AIM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Aim Immunotech generated $170K in revenue in fiscal year 2024. This represents a decrease of 15.8% from the prior year.
Aim Immunotech's EBITDA was -$19.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 38.4% from the prior year.
Aim Immunotech generated -$14.9M in free cash flow in fiscal year 2024, representing cash available after capex.
Aim Immunotech reported -$17.3M in net income in fiscal year 2024. This represents an increase of 40.2% from the prior year.
Aim Immunotech earned $-0.31 per diluted share (EPS) in fiscal year 2024. This represents an increase of 48.3% from the prior year.
Aim Immunotech held $1.7M in cash against $2.8M in long-term debt as of fiscal year 2024.
Aim Immunotech had 655,263 shares outstanding in fiscal year 2024. This represents a decrease of 98.7% from the prior year.
Aim Immunotech's operating margin was -11630.6% in fiscal year 2024, reflecting core business profitability. This is up 4169.4 percentage points from the prior year.
Aim Immunotech's net profit margin was -10188.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 4149.4 percentage points from the prior year.
Aim Immunotech invested $6.2M in research and development in fiscal year 2024. This represents a decrease of 43.3% from the prior year.
Aim Immunotech invested $18K in capex in fiscal year 2024, funding long-term assets and infrastructure.
AIM Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26K+4.0% | $25K+56.3% | $16K-64.4% | $45K-10.0% | $50K+25.0% | $40K-38.5% | $65K+41.3% | $46K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $607K-48.3% | $1.2M+8.7% | $1.1M-35.1% | $1.7M+45.3% | $1.1M-41.3% | $2.0M-39.0% | $3.2M+17.0% | $2.7M |
| SG&A Expenses | $1.8M+20.9% | $1.5M-41.6% | $2.5M-39.8% | $4.2M+63.2% | $2.6M-32.1% | $3.8M-64.9% | $10.9M+99.6% | $5.4M |
| Operating Income | -$2.4M+7.5% | -$2.6M+26.9% | -$3.6M+38.2% | -$5.9M-58.5% | -$3.7M+35.6% | -$5.7M+59.1% | -$14.0M-71.7% | -$8.2M |
| Interest Expense | $148K-0.7% | $149K+20.2% | $124K-6.1% | $132K-26.3% | $179K+148.6% | $72K | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.3M-17.5% | -$2.8M+24.6% | -$3.7M+37.9% | -$6.0M-225.0% | -$1.8M+68.4% | -$5.8M+53.7% | -$12.6M-60.9% | -$7.8M |
| EPS (Diluted) | $1.57+142.7% | $-3.68 | $-0.05 | $8.81 | $-3.00-2400.0% | $-0.12+53.8% | $-0.26-62.5% | $-0.16 |
AIM Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.5M+33.1% | $4.1M-33.9% | $6.2M-27.4% | $8.6M-45.2% | $15.7M-2.9% | $16.2M-16.5% | $19.4M-30.4% | $27.9M |
| Current Assets | $2.6M+151.2% | $1.0M-60.3% | $2.6M-38.1% | $4.2M-59.7% | $10.4M-8.4% | $11.3M-22.3% | $14.6M-36.0% | $22.7M |
| Cash & Equivalents | $2.3M+393.1% | $476K-47.0% | $898K-47.2% | $1.7M-52.1% | $3.6M+7.9% | $3.3M-39.4% | $5.4M-64.4% | $15.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $1.2M+2366.7% | $48K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $11.6M+8.4% | $10.7M+5.6% | $10.1M+1.8% | $9.9M+3.3% | $9.6M-15.4% | $11.4M+24.2% | $9.1M+73.9% | $5.3M |
| Current Liabilities | $4.0M-61.1% | $10.4M+6.4% | $9.8M+2.4% | $9.5M+7.8% | $8.8M-10.5% | $9.9M+14.1% | $8.7M+83.5% | $4.7M |
| Long-Term Debt | N/A | $2.7M+14.0% | $2.4M-15.0% | $2.8M+891.9% | $283K-70.2% | $950K | N/A | N/A |
| Total Equity | -$6.1M+7.2% | -$6.5M-69.7% | -$3.9M-191.8% | -$1.3M-121.7% | $6.1M+26.4% | $4.8M-52.8% | $10.2M-54.7% | $22.6M |
| Retained Earnings | -$436.6M-0.8% | -$433.3M-0.6% | -$430.5M-0.9% | -$426.8M-2.3% | -$417.2M-0.4% | -$415.3M-1.4% | -$409.5M-3.2% | -$396.9M |
AIM Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.1M-231.7% | -$1.5M+35.2% | -$2.4M+40.3% | -$4.0M-31.5% | -$3.0M+37.5% | -$4.8M+50.7% | -$9.8M-72.1% | -$5.7M |
| Capital Expenditures | N/A | N/A | N/A | $0 | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | -$4.0M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $296K-60.7% | $754K-16.0% | $898K-75.8% | $3.7M+348.4% | $826K+622.8% | -$158K+26.2% | -$214K+36.3% | -$336K |
| Financing Cash Flow | $6.7M+1774.4% | $355K-46.2% | $660K-36.4% | $1.0M-57.5% | $2.4M-13.7% | $2.8M+1824.5% | $147K-36.9% | $233K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AIM Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -9411.5%+1172.5pp | -10584.0%+12034.8pp | -22618.8%-9607.6pp | -13011.1%-5623.1pp | -7388.0%+6947.0pp | -14335.0%+7208.1pp | -21543.1%-3810.5pp | -17732.6% |
| Net Margin | -12630.8%-1454.8pp | -11176.0%+11980.3pp | -23156.3%-9896.3pp | -13260.0%-9588.0pp | -3672.0%+10870.5pp | -14542.5%+4805.2pp | -19347.7%-2356.4pp | -16991.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -59.8%+7.9pp | -67.7%-8.4pp | -59.3%+10.0pp | -69.3%-57.6pp | -11.7%+24.3pp | -35.9%+29.0pp | -64.9%-36.8pp | -28.1% |
| Current Ratio | 0.64+0.5 | 0.10-0.2 | 0.26-0.2 | 0.44-0.7 | 1.17+0.0 | 1.14-0.5 | 1.68-3.1 | 4.82 |
| Debt-to-Equity | -1.90-1.5 | -0.42+0.2 | -0.62+1.5 | -2.12-2.2 | 0.05-0.2 | 0.20-0.7 | 0.89+0.7 | 0.23 |
| FCF Margin | N/A | N/A | N/A | -8788.9% | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.44), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Aim Immunotech's annual revenue?
Aim Immunotech (AIM) reported $170K in total revenue for fiscal year 2024. This represents a -15.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aim Immunotech's revenue growing?
Aim Immunotech (AIM) revenue declined by 15.8% year-over-year, from $202K to $170K in fiscal year 2024.
Is Aim Immunotech profitable?
No, Aim Immunotech (AIM) reported a net income of -$17.3M in fiscal year 2024, with a net profit margin of -10188.2%.
What is Aim Immunotech's earnings per share (EPS)?
Aim Immunotech (AIM) reported diluted earnings per share of $-0.31 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Aim Immunotech's EBITDA?
Aim Immunotech (AIM) had EBITDA of -$19.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Aim Immunotech have?
As of fiscal year 2024, Aim Immunotech (AIM) had $1.7M in cash and equivalents against $2.8M in long-term debt.
What is Aim Immunotech's operating margin?
Aim Immunotech (AIM) had an operating margin of -11630.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Aim Immunotech's net profit margin?
Aim Immunotech (AIM) had a net profit margin of -10188.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Aim Immunotech's free cash flow?
Aim Immunotech (AIM) generated -$14.9M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aim Immunotech's operating cash flow?
Aim Immunotech (AIM) generated -$14.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aim Immunotech's total assets?
Aim Immunotech (AIM) had $8.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Aim Immunotech's capital expenditures?
Aim Immunotech (AIM) invested $18K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Aim Immunotech spend on research and development?
Aim Immunotech (AIM) invested $6.2M in research and development during fiscal year 2024.
How many shares does Aim Immunotech have outstanding?
Aim Immunotech (AIM) had 655,263 shares outstanding as of fiscal year 2024.
What is Aim Immunotech's current ratio?
Aim Immunotech (AIM) had a current ratio of 0.44 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Aim Immunotech's debt-to-equity ratio?
Aim Immunotech (AIM) had a debt-to-equity ratio of -2.12 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aim Immunotech's return on assets (ROA)?
Aim Immunotech (AIM) had a return on assets of -201.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aim Immunotech's cash runway?
Based on fiscal year 2024 data, Aim Immunotech (AIM) had $1.7M in cash against an annual operating cash burn of $14.9M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aim Immunotech's debt-to-equity ratio negative or unusual?
Aim Immunotech (AIM) has negative shareholder equity of -$1.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aim Immunotech's Piotroski F-Score?
Aim Immunotech (AIM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aim Immunotech's earnings high quality?
Aim Immunotech (AIM) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aim Immunotech cover its interest payments?
Aim Immunotech (AIM) has an interest coverage ratio of -33.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aim Immunotech?
Aim Immunotech (AIM) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.